NEW YORK, NY / ACCESSWIRE / May 19, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Mobile TeleSystems PJSC (MBT)
Class Period: March 19, 2014 to March 7, 2019
Lead Plaintiff Deadline: May 20, 2019

The lawsuit alleges that Mobile TeleSystems PJSC made materially false and/or misleading statements and/or failed to disclose that: (1) MTS and its subsidiary were involved in a scheme to pay $420 million in bribes in Uzbekistan; (2) consequently, MTS knew or should have known it would be forced to pay substantial fines to the U.S. government after disclosing in 2014 that the U.S. Department of Justice and Securities and Exchange Commission were investigating its Uzbekistan operations; (3) MTS' level of cooperation with the U.S. government and remediation was lacking; (4) due to the aforementioned misconduct, MTS would be forced to pay approximately $850 million in criminal penalties to the U.S. government; and (5) as a result, defendants' public statements were materially false and/or misleading at all relevant times.

Get additional information about the MBT lawsuit: http://www.kleinstocklaw.com/pslra-1/mobile-telesystems-pjsc-loss-submission-form?id=1574&from=1

American Renal Associates Holdings, Inc. (ARA)
Class Period: August 10, 2016 to March 27, 2019
Lead Plaintiff Deadline: May 28, 2019

Throughout the class period, American Renal Associates Holdings, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) issues with American Renal's accounting process for revenue recognition, collections, and related matters would give rise to a U.S. Securities and Exchange Commission ("SEC") investigation into the same, and increased regulatory scrutiny by the SEC; (2) financial statements for the fiscal years 2014, 2015, 2016 and 2017 contained in its Annual Reports for the years ended December 31, 2016 and 2017, and its condensed consolidated financial statements in quarterly reports from 2016 through 2018, were false and could not be relied upon; (3) American Renal had material weaknesses in its internal control over financial reporting; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times.

Get additional information about the ARA lawsuit: http://www.kleinstocklaw.com/pslra-1/american-renal-associates-holdings-inc-loss-submission-form?id=1574&from=1